587. Impact of the infectious site infection with Staphylococcus aureus in Europe: results from the economics of the SALT study
Authors: Salmanton-Garcia Jon , Bruns Caroline , Rutz Jule , Albertsmeier Markus , Ankert Juliane , Bernard Louis , Bataille Camille , Couvé-Deacon Elodie , Fernández-Ferrer María , Fortún Jesús , Galar Alicia , Grill Eva , Guimard Thomas , Vehreschild Jörg-Janne , Stemler Jannik , Naendrup Jan-Hendrik , Hampl Jürgen , Tallon Bradly , Sprute Rosanne , Pablo Horcajada Juan , Mollar-Maseres Joan , Muñoz Patricia , Pletz Mathias , Serracino-Inglott Ferdinand , Soriano Alex , Vilz Tim , Seifert Harald , Cornely Oliver A , Mellinghoff Sibylle , Liss Blasius , Wingen-Heimann Sebastian 
Published: January 2025

Abstract

Background
Surgical site infections (SSI), mainly caused by Staphylococcus aureus, represent a significant economic burden in Europe, leading to an increase in length of hospitalization, mortality and treatment costs, especially with drug-resistant strains. such as methicillin-resistant Staphylococcus aureus. A new case-control study in high-volume centers aims to provide detailed data on the economic impact of treating Staphylococcus aureus SSIs.

Methods
The SALT study is a multinational retrospective cohort study with a case-control analysis focused on Staphylococcus aureus SSIs in Europe. The study included participants from France, Germany, Italy, Spain, and the United Kingdom who underwent invasive surgery in 2016 and employed a microcosting approach to assess health economic factors, matching Staphylococcus aureus SSI cases with controls.

Results
In 2016, among 178,904 surgical patients in five European countries, 764 developed Staphylococcus aureus SSI. By matching 744 cases with controls, the study revealed that Staphylococcus aureus SSI cases incurred higher immediate hospitalization costs (€8,809.9), compared to controls (€6,032.4). Furthermore, Staphylococcus aureus SSI cases exhibited higher costs for readmissions within the first year after surgery (€7,961.6 versus €5,298.6), with significant differences observed. Factors associated with an increase in surgery-related costs included the cost of hospitalization immediately after surgery, first ICU admission within 12 months, and hospital readmission within 12 months, as identified by analysis multivariable.

Conclusion
The higher rates of hospitalization, ICU admissions, and readmissions among Staphylococcus aureus SSI cases highlight the severity of these infections and their impact on healthcare costs, emphasizing the potential benefits of infection control measures based on evidence and improved patient care to mitigate the economic burden.

Disclosures
Thomas Guimard, MD, Gilead: Convention invitation|Menarini France: Hospitality|MSD: Hospitality|Pfizer: Advisor/Consultant|Shionogi BV: Hospitality Oliver A. Cornely, Prof. Dr., Abbott: Honoraria|Abbvie: Advisor/Consultant|Abbvie: Honoraria|AiCuris: Advisor/Consultant|Akademie fur Infektionmedizin: Honoraria|Al-Jazeera Pharmaceuticals/Hikma: Honoraria|amedes: Honoraria|AstraZeneca: Honoraria|Basilea: Advisor/Consultant|Biocon: Advisor/Consultant|BMBF: Grant/Research Support|Boston Strategic Partners: Advisor/Consultant|CIdara: Advisor/Consultant|CIdara: Expert Testimony|CIdara: Grant/Research Support|CIdara: Participation on a DRC or DSMB|CoRe Consulting: Stocks/Bonds (Private Company)|Deutscher Arzteverlag: Honoraria|DZIF: Grant/Research Support|EasyRadiology: Stocks/Bonds (Private Company)|EU-DG RTD: Grant/Research Support|F2G: Grant/Research Support|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Gilead: Honoraria|Grupo Biotoscana/United Medical/Knight: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria|IQVIA: Advisor/Consultant|IQVIA: Participation on a DRC or DSMB|Janssen: Advisor/Consultant|Janssen: Participation on a DRC or DSMB|Matinas: Advisor/Consultant|MedPace: Advisor/Consultant|MedPace: Grant/Research Support|MedPace: Participation on a DRC or DSMB|Medscape/WebMD: Honoraria|MedUpdate: Honoraria|Menarini: Advisor/Consultant|Moderna: Honoraria|Molecular Partners: Advisor/Consultant|MSD: Grant/Research Support|MSD: Honoraria|MSG-ERC: Advisor/Consultant|Mundipharma: Advisor/Consultant|Mundipharma: Grant/Research Support|Mundipharma: Honoraria|Noscendo: Honoraria|Noxxon: Advisor/Consultant|Octapharma: Advisor/Consultant|Octapharma: Grant/Research Support|Pardes: Advisor/Consultant|Partner Therapeutics: Advisor/Consultant|Patent: US18/562644|Paul-Martini-Stiftung: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Pfizer: Honoraria|PSI: Advisor/Consultant|PSI: Participation on a DRC or DSMB|Pulmocide: Participation on a DRC or DSMB|Sandoz: Honoraria|Scynexis: Advisor/Consultant|Scynexis: Grant/Research Support|Seqirus: Advisor/Consultant|Seqirus: Honoraria|Seres: Advisor/Consultant|Shionogi: Advisor/Consultant|Shionogi: Honoraria|streamedup!: Honoraria|The Prime Meridian Group: Advisor/Consultant|Touch Independent: Honoraria|Vitis: Honoraria